ADC drugs targeting trophoblast cell surface antigen 2 (TROP‐2), including datopotamab deruxtecan, sacituzumab govitecan, and SHR‐A1921, showed promising efficacy in post‐line treatment of advanced NSCLC and there are currently ongoing clinical trials exploring the efficacy of TROP‐2 ADC drugs for patients who failed first‐line chemo‐immunotherapy (NCT05687266, NCT05609968, and NCT06480136). Here, TACSTD2 is linked to non-small cell lung carcinoma.